

## EXERCISE OF OPTIONS PROGRAM 2020/23

**Surgical Science's options program 2020/23 has been redeemed by the option holders resulting in an increase in the number of shares in the company by 225,000, to 51,026,236 shares. As a result, the share capital increases by SEK 11,250 to SEK 2,551,312. In connection with this, CEO Gisli Hennermark has exercised 37,500 options, after which he has sold 37,500 shares. CFO Anna Ahlberg has exercised 7,500 options, after which she has sold 6,000 of these.**

At Surgical Sciences' Annual General Meeting on May 6, 2020, it was resolved to establish an incentive program of a maximum of 300,000 warrants for the company's employees. Each warrant gave the right to subscribe for one share in the company for SEK 85.10 during the period May 15 – July 15, 2023. A total of 225,000 options were subscribed for of the options program.

The options have now been exercised by the option holders which means that Surgical Science's share capital increases by SEK 11,250 and the number of shares increases by 225,000, corresponding to a dilution of approximately 0.4 percent of the total number of shares and votes. Surgical Science has thus received SEK 19,147,500 in cash.

In connection with the redemption procedure, CEO Gisli Hennermark has exercised 37,500 options, after which he has sold 37,500 shares. Gisli Hennermark's total shareholding in Surgical Science amounts to 342,200 shares after the transactions. CFO Anna Ahlberg has exercised 7,500 options, after which she has sold 6,000 shares. Anna Ahlberg's total shareholding in Surgical Science amounts to 24,000 shares after the transactions. The transactions are reported to the Swedish Financial Supervisory Authority in accordance with applicable regulations.

Following the exercise of the options, 181,900 shares have been sold to a few institutional investors in a process managed by Pareto Securities.

Gothenburg, Sweden, June 2, 2023  
Surgical Science Sweden AB (publ)

**The press release is available in the attachment or via**

<https://surgicalscience.com/aktien/pressmeddelanden/>

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

**For further information, please contact:**

---

Gisli Hennermark, CEO  
Telephone: +46-70-420 83 00  
E-mail: [gisli.hennermark@surgicalscience.com](mailto:gisli.hennermark@surgicalscience.com)

Anna Ahlberg, CFO  
Telephone: +46-70-855 38 35  
E-mail: [anna.ahlberg@surgicalscience.com](mailto:anna.ahlberg@surgicalscience.com)

**About Surgical Science Sweden AB (publ)**

---

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 250 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

**Attachments**

---

[EXERCISE OF OPTIONS PROGRAM 2020/23](#)